|
1
|
Westlake S and Cooper N: Cancer incidence
and mortality: Trends in the United Kingdom and constituent
countries, 1993 to 2004. Health Stat Q. 33–46. 2008.PubMed/NCBI
|
|
2
|
Carlson RW, Allred DC, Anderson BO,
Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein
LJ, Gradishar WJ, et al: Metastatic breast cancer, version 1.2012:
Featured updates to the NCCN guidelines. J Natl Compr Canc Netw.
10:821–829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Demicheli R, Ardoino I, Boracchi P,
Coradini D, Agresti R, Ferraris C, Gennaro M, Hrushesky WJ and
Biganzoli E: Recurrence and mortality according to estrogen
receptor status for breast cancer patients undergoing conservative
surgery. Ipsilateral breast tumour recurrence dynamics provides
clues for tumour biology within the residual breast. BMC Cancer.
10:6562010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Faverly DR, Hendriks JH and Holland R:
Breast carcinomas of limited extent: Frequency,
radiologic-pathologic characteristics, and surgical margin
requirements. Cancer. 91:647–659. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bitterman A, Kessner R, Goldman I, Shiloni
E and Steiner M: Intraoperative radiotherapy for breast cancer. Isr
Med Assoc J. 14:256–259. 2012.PubMed/NCBI
|
|
6
|
Murawa P, Murawa D, Adamczyk B and Polom
K: Breast cancer: Actual methods of treatment and future trends.
Rep Pract Oncol Radiother. 19:165–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sedlmayer F, Reitsamer R, Fussl C, Ziegler
I, Zehentmayr F, Deutschmann H, Kopp P and Fastner G: Boost IORT in
breast cancer: Body of evidence. Int J Breast Cancer.
2014:4725162014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Belletti B, Vaidya JS, D'Andrea S,
Entschladen F, Roncadin M, Lovat F, Berton S, Perin T, Candiani E,
Reccanello S, et al: Targeted intraoperative radiotherapy impairs
the stimulation of breast cancer cell proliferation and invasion
caused by surgical wounding. Clin Cancer Res. 14:1325–1332. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Segatto I, Berton S, Sonego M, Massarut S,
Perin T, Piccoli E, Colombatti A, Vecchione A, Baldassarre G and
Belletti B: Surgery-induced wound response promotes stem-like and
tumor-initiating features of breast cancer cells, via STAT3
signaling. Oncotarget. 5:6267–6279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zaleska K, Suchorska WM, Przybyła A and
Murawa D: Effect of surgical wound fluids after intraoperative
electron radiotherapy on the cancer stem cell phenotype in a panel
of human breast cancer cell lines. Oncol Lett. 12:3707–3714.
2016.PubMed/NCBI
|
|
11
|
Kong W, He L, Coppola M, Guo J, Esposito
NN, Coppola D and Cheng JQ: MicroRNA-155 regulates cell survival,
growth and chemosensitivity by targeting FOXO3a in breast cancer. J
Biol Chem. 285:17869–17879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
De Mattos-Arruda L, Bottai G, Nuciforo PG,
Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J,
Masci G, Corsi F, et al: MicroRNA-21 links
epithelial-to-mesenchymal transition and inflammatory signals to
confer resistance to neoadjuvant trastuzumab and chemotherapy in
HER2-positive breast cancer patients. Oncotarget. 6:37269–37280.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Leung CM, Chen TW, Li SC, Ho MR, Hu LY,
Liu WS, Wu TT, Hsu PC, Chang HT and Tsai KW: MicroRNA expression
profiles in human breast cancer cells after multifraction and
single-dose radiation treatment. Oncol Rep. 31:2147–2156. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Prat A and Perou CM: Deconstructing the
molecular portraits of breast cancer. Mol Oncol. 5:5–23. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Neve RM, Chin K, Fridlyand J, Yeh J,
Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A
collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cancer Cell. 10:515–527.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Demicheli R, Valagussa P and Bonadonna G:
Does surgery modify growth kinetics of breast cancer
micrometastases? Br J Cancer. 85:490–492. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fisher B, Gunduz N, Coyle J, Rudock C and
Saffer E: Presence of a growth-stimulating factor in serum
following primary tumor removal in mice. Cancer Res. 49:1996–2001.
1989.PubMed/NCBI
|
|
19
|
Holmgren L, O'Reilly MS and Folkman J:
Dormancy of micrometastases: Balanced proliferation and apoptosis
in the presence of angiogenesis suppression. Nat Med. 1:149–153.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Segatto I, Berton S, Sonego M, Massarut S,
Fabris L, Armenia J, Mileto M, Colombatti A, Vecchione A,
Baldassarre G and Belletti B: p70S6 kinase mediates breast cancer
cell survival in response to surgical wound fluid stimulation. Mol
Oncol. 8:766–780. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Segatto I, Berton S, Sonego M, Massarut S,
D'Andrea S, Perin T, Fabris L, Armenia J, Rampioni G, Lovisa S, et
al: Inhibition of breast cancer local relapse by targeting p70S6
kinase activity. J Mol Cell Biol. 5:428–431. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fidler IJ: The organ microenvironment and
cancer metastasis. Differentiation. 70:498–505. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paget S: The distribution of secondary
growths in cancer of the breast. 1889. Lancet. 133:571–573. 1889.
View Article : Google Scholar
|
|
24
|
Barcellos-Hoff MH, Park C and Wright EG:
Radiation and the microenvironment-tumorigenesis and therapy. Nat
Rev Cancer. 5:867–875. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vaidya JS, Tobias JS, Baum M, Keshtgar M,
Joseph D, Wenz F, Houghton J, Saunders C, Corica T, D'Souza D, et
al: Intraoperative radiotherapy for breast cancer. Lancet Oncol.
5:165–173. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chaudhry MA: Real-time PCR analysis of
micro-RNA expression in ionizing radiation-treated cells. Cancer
Biother Radiopharm. 24:49–56. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Weidhaas JB, Babar I, Nallur SM, Trang P,
Roush S, Boehm M, Gillespie E and Slack FJ: MicroRNAs as potential
agents to alter resistance to cytotoxic anticancer therapy. Cancer
Res. 67:11111–11116. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Maes OC, An J, Sarojini H, Wu H and Wang
E: Changes in MicroRNA expression patterns in human fibroblasts
after low-LET radiation. J Cell Biochem. 105:824–34. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tagliabue E, Agresti R, Carcangiu ML,
Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco
M, Balsari A and Ménard S: Role of HER2 in wound-induced breast
carcinoma proliferation. Lancet. 362:527–533. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kraemer A, Anastasov N, Angermeier M,
Winkler K, Atkinson MJ and Moertl S: MicroRNA-mediated processes
are essential for the cellular radiation response. Radiation Res.
176:575–586. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang H, Kong W, He L, Zhao JJ, O'Donnell
JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ:
MicroRNA expression profiling in human ovarian cancer: miR-214
induces cell survival and cisplatin resistance by targeting PTEN.
Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo
YY: MicroRNA-21 targets tumor suppressor genes in invasion and
metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K
and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN
and promotes growth and invasion in non-small cell lung cancer
(NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li X, Xin S, He Z, Che X, Wang J, Xiao X,
Chen J and Song X: MicroRNA-21 (miR-21) post-transcriptionally
downregulates tumor suppressor PDCD4 and promotes cell
transformation, proliferation, and metastasis in renal cell
carcinoma. Cell Physiol Biochem. 33:1631–1642. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fujita S, Ito T, Mizutani T, Minoguchi S,
Yamamichi N, Sakurai K and Iba H: miR-21 gene expression triggered
by AP-1 is sustained through a double-negative feedback mechanism.
J Mol Biol. 378:492–504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Anastasov N, Höfig I, Vasconcellos IG,
Rappl K, Braselmann H, Ludyga N, Auer G, Aubele M and Atkinson MJ:
Radiation resistance due to high expression of miR-21 and G2/M
checkpoint arrest in breast cancer cells. Radiat Oncol. 7:2062012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk
ML and Struhl K: STAT3 activation of miR-21 and miR-181b-1 via PTEN
and CYLD are part of the epigenetic switch linking inflammation to
cancer. Mol Cell. 39:493–506. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ross JS, Slodkowska EA, Symmans WF,
Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and
breast cancer: Ten years of targeted anti-HER-2 therapy and
personalized medicine. Oncologist. 14:320–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Slamon DJ, Godolphin W, Jones LA, Holt JA,
Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee JA, Lee HY, Lee ES, Kim I and Bae JW:
Prognostic implications of microRNA-21 overexpression in invasive
ductal carcinomas of the breast. J Breast Cancer. 14:269–275. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen
J, Su F, Yao H and Song E: Up-regulation of miR-21 mediates
resistance to trastuzumab therapy for breast cancer. J Biol Chem.
286:19127–19137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang CM, Zhao J and Deng HY: MiR-155
promotes proliferation of human breast cancer MCF-7 cells through
targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci.
20:792013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen X, Chen Y, Wang Y, Yan M, Zhang J,
Liu Q, Yang H and Li J: Role of miR-155 in myasthenia gravis and
effect of dexamethasone on miR-155. Zhong Nan Da Xue Xue Bao Yi Xue
Ban. 37:777–782. 2012.(In Chinese). PubMed/NCBI
|
|
44
|
Cortez MA, Welsh JW and Calin GA:
Circulating microRNAs as noninvasive biomarkers in breast cancer.
Recent Results Cancer Res. 195:151–161. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shibuya H, Iinuma H, Shimada R, Horiuchi A
and Watanabe T: Clinicopathological and prognostic value of
microRNA-21 and microRNA-155 in colorectal cancer. Oncology.
79:313–320. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu
H, Liu MF and Wang ED: MicroRNA-155 functions as an OncomiR in
breast cancer by targeting the suppressor of cytokine signaling 1
gene. Cancer Res. 70:3119–3127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gasparini P, Lovat F, Fassan M, Casadei L,
Cascione L, Jacob NK, Carasi S, Palmieri D, Costinean S, Shapiro
CL, et al: Protective role of miR-155 in breast cancer through
RAD51 targeting impairs homologous recombination after irradiation.
Proc Natl Acad Sci USA. 111:4536–4541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen J, Wang BC and Tang JH: Clinical
significance of microRNA-155 expression in human breast cancer. J
Surg Oncol. 106:260–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Garofalo M, Quintavalle C, Romano G, Croce
CM and Condorelli G: miR221/222 in cancer: Their role in tumor
progression and response to therapy. Curr Mol Med. 12:27–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pineau P, Volinia S, McJunkin K, Marchio
A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM and
Dejean A: miR-221 overexpression contributes to liver
tumorigenesis. Proc Natl Acad Sci USA. 107:264–269. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Garofalo M, Quintavalle C, Di Leva G,
Zanca C, Romano G, Taccioli C, Liu CG, Croce CM and Condorelli G:
MicroRNA signatures of TRAIL resistance in human non-small cell
lung cancer. Oncogene. 27:3845–3855. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pallante P, Visone R, Ferracin M, Ferraro
A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M,
Negrini M, et al: MicroRNA deregulation in human thyroid papillary
carcinomas. Endocr Relat Cancer. 13:497–508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Roscigno G, Quintavalle C, Donnarumma E,
Puoti I, Diaz-Lagares A, Iaboni M, Fiore D, Russo V, Todaro M,
Romano G, et al: MiR-221 promotes stemness of breast cancer cells
by targeting DNMT3b. Oncotarget. 7:580–592. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ke J, Zhao Z, Hong SH, Bai S, He Z, Malik
F, Xu J, Zhou L, Chen W, Martin-Trevino R, et al: Role of
microRNA221 in regulating normal mammary epithelial hierarchy and
breast cancer stem-like cells. Oncotarget. 6:3709–3721. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhao JJ, Lin J, Yang H, Kong W, He L, Ma
X, Coppola D and Cheng JQ: MicroRNA-221/222 negatively regulates
estrogen receptor alpha and is associated with tamoxifen resistance
in breast cancer. J Biol Chem. 283:31079–31086. 2008. View Article : Google Scholar : PubMed/NCBI
|
